The role of 15-lipoxygenase in atherogenesis: Pro- and antiatherogenic actions

Current Opinion in Lipidology

Volumn 8, Issue 2, 1997, Pages 111-117

  Kühn, Hartmut ^a   Chan, Lawrence ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ARACHIDONATE 15 LIPOXYGENASE; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; CELL ADHESION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPID OXIDATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; REVIEW; STEREOCHEMISTRY; TRANSCRIPTION REGULATION; TRANSGENIC ANIMAL; TRANSLATION REGULATION;

EID: 0030995346     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199704000-00009     Document Type: Review

References (68)

1. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
2. Steinberg DS, Parthasarathy TE, Carew JC, Khoo, Witztum JL: Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
3. Holvoet P, Collen C: Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J 1994, 8:1284-1297.
4. Stocker R: Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994, 5:422-433.
5. Parthasarathy S, Santanam N: Mechanisms of oxidation, antioxidants and atherosclerosis. Curr Opin Lipidol 1994, 5:371-375.
6. Esterbauer H, Ramos P: Chemistry and pathophysiology of oxidation of LDL. Rev Physiol Biochem Pharmacol 1995, 127:31-34. This paper constitutes a comprehensive review of the chemistry and pathophysiology of LDL oxidation and its potential role in atherogenesis. Particular emphasis is given to the composition of LDL lipids and to the mechanisms of the oxidative processes involved.
7. Tribble DL: Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol 1995, 6:196-208.
8. Jialal I, Devaraj S: Low-density lipoprotein oxidation, antioxidants and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996, 42:498-506.
9. Kühn H, Belkner J, Wiesner R, Schewe T, Lankin VZ, Tikhaze AK: Structure elucidation of oxygenated lipids in human atherosclerotic lesions. Eicosanoids 1992, 5:17-22.
10. Kühn H, Belkner J, Zaiss S, Fahrenklemper T, Wohlfeil S: Involvement of 15-lipoxygenase in early stages of atherogensis. J Exp Med 1994, 179:1903-1911.
11. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcardt MK: Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 1995, 96:504-510. In this study a share of specific LOX products was detected in human atherosclerotic lesions indicating the in-vivo action of 15-LOX in the lesion. These data extend the findings obtained for cholesterol-fed rabbits [10] to the human situation.
12. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JT, Steinberg D: Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rlch areas of atherosclerotic lesions. Proc Natl Acad Sci U S A 1990, 87:6959-6963.
13. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Sarkioia T, Witztum JT, Steinberg D: Gene expression in macrophage rich human atherosclerotic lesions. J Clin Invest 1991, 87:1146-1152.
14. Webb EC: Enzyme nomenclature. Recommendations of the nomenclature committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. Edited by Webb EC. San Diego: Academic Press; 1992.
15. Yamamoto S: Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992, 1128:117-131.
16. Lewis RA, Austen AF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990, 323:645-655.
17. Rapoport SM, Schewe T, Thiele B: Maturational breakdown of mitochondria and other organelles in reticulocytes. Blood Cell Biochem 1990, 1:151-194.
18. Serhan CN: Lipoxins: eicosanoids carrying intracellular and intercellular messages J Bioenerg Biomem 1991, 23:105-122.
19. Kühn H: Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)xy-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)xy-9Z,11E-octadecadienoic acid. Prog Lipid Res 1997 (In press).
20. Gan QF, Witkop GL, Sloane DL, Straub KM, Sigal E: Identification of a specific methionine in mammalian 15-lipoxygenase which is oxygenated by the enzyme product 13-HODE: dissociation of sulfoxide formation from self-inactivation. Biochemistry 1995, 34:7069-7079.
21. Kishimoto K, Nakamura M, Suzuki H, Yoshimoto T, Yamamoto S: Incorporation of 15-hydroperoxy-5,8,11,13-eicosatetraenolc acid derivative into the porcine leukocyte 12-lipoxygenase associated with its suicidal inactivation. Biochim Biophys Acta 1996, 1300:56-62.
22. Schnurr K, Belkner J, Ursini F, Schewe T, Kühn H: The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products. J Biol Chem 1996, 271:4653-4658.
23. Toh H, Yokoyama C, Tanabe T, Yoshimoto T, Yamamoto S: Molecular evolution of cyclooxygenase and lipoxygenase. Prostaglandins 1992, 44:291-315.
24. Kühn H, Belkner J, Suzuki H, Yamamoto S: Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J Lipid Res 1994, 35:1749-1759.
25. Prigge ST, Boyington JC, Gaffney BJ, Amsel LM: Structure conservation in lipoxygenases: structural analysis of soybean lipoxygenase-1 and modelling of human lipoxygenases. Proteins 1996, 24:275-291.
26. Gan QF, Browner MF, Sloane DL, Sigal E: Defining the arachidonic acid binding site of human 15-lipoxygenase. J Biol Chem 1996, 271: 25412-25418.
27. Conrad DJ, Kühn H, Mulkins M, Highland E, Sigal E: Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci U S A 1992, 89:217-221.
28. Nassar GM, Morrow JD, Roberts J II, Lakkis FG, Badr KF: Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994, 269:27631-27634.
29. Brinckmann R, Topp M, Zalan I, Heydeck D, Ludwig P, Kühn H, Berdel WE, Habenicht AJR: The regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin 4. Biochem J 1996, 318:305-312.
30. Montero A, Nassar GM, Badr KF: Regulation of 15-lipoxygenase mRNA expression in human monocytes in response to interleukln 13. Prostaglandins, Leukot Essent Fatty Acids 1996, 55(Suppl 1):98.
31. Kühn H, Thiele BJ: Molecular biology of 15-lipoxygenase. J Lipid Med Cell Signaling 1995, 12:157-170.
32. Ostareck-Lederer A, Ostareck DH, Standart N, Thiele BJ: Translation of 15-lipoxygenase is inhibited by a protein that binds to a repeated sequence in the 3′ untranslated region. EMBO J 1994, 13:1476-1481.
33. Schilstra MJ, Veldink GA, Vliegenthart JFG: The dioxygenation rate in lipoxygenase catalysis is determined by the amount of iron(III) lipoxygenase in solution. Biochemistry 1994, 33:3974-3979.
34. Chasteen ND, Grady JK, Skorey KI, Neden KJ, Riendeau D, Percival DM: Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence, and ultraviolet-visible spectroscopy. Redox cycling between ferrous and ferric state. Biochemistry 1993, 32, 9763-9771.
35. Nelson MJ, Chase DB, Seitz SP: Photolysis of 'purple' lipoxygenase: implication for the structure of the chromophore. Biochemistry 1995, 34:6159-6163.
36. Lankin VZ, Kühn H, Hiebsch C, Schewe T, Rapoport SM, Tichase AK, Gordeeva NT: On the nature of the stimulation of the lipoxygenase from reticulocytes by biological membranes. Biomed Biochim Acta 1985,44:655-664.
37. Ford-Hutchinson AW: FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci 1991, 121:68-70.
38. Tangirala RK, Casanada F, Miller E, Witztum JL, Steinberg D, Palinski W: Effect of the antioxidant N,N′-diphenyl 1,4-phenylendlamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1995, 15:1625-1630.
39. Chang MY, Sasahara M, Chait A, Raines EW, Ross R: Inhibition of hypercholesterolemia induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995, 15:1631-1640.
40. Henriksson P, Hamberg M, Diczfalusy U: Formation of 15-HETE as a major hydroxeicosatetraenoic acid in the atherosclerotic vessel wall. Biochim Biophys Acta 1985, 834: 272-274.
41. Simon TC, Makheja AN, Bailey JM: Formation of 15-hydroxyeicosatetraenoic acid (15-HETE) as the predominant eicosanoid in aorta from Watanabe heritable hyperlipidemic and cholesterol fed rabbits. Atherosclerosis 1989, 75:31-38.
42. Hiltunen T, Luoma J, Nikkari T, Ylä-Herttuala S: Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. Circulation 1995, 92:3297-3303.
43. Bailey MJ, Makhej AN, Lee R, Simon TC: Systemic activation of 15-lipoxygenase in heart, lung and vascular tissue by hypercholesterolemla: relationship to lipoprotein oxidation and atherogenesis. Atherosclerosis 1995, 113:247-258.
44. 2 mimics cell-mediated oxidative modification. J Lipid Res 1988, 29:745-753.
45. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, Kühn H: Oxygenation of lipoproteins by mammalian lipoxygenases. Bur J Biochem 1993, 213:251-261.
46. Lass A, Belkner J, Esterbauer H, Kühn H: lipoxygenase treatment renders low density lipoprotein susceptible to copper catalyzed oxidation. Biochem J 1996, 314:577-585. In this paper the concerted interaction of enzymatic and nonenzymatic lipid peroxidation was studied in vitro. The reconstituted system used may be regarded as a suitable model system reflecting the oxidative events in the developing lesion. A major finding of this study was the fact that 15-LOX catalysed LDL oxidation proceeds in the presence of lipophilic antioxidants. This result may be important for strategies aimed at designing antioxidants for treatment of atherosclerosis.
47. O'Leary VJ, Darley-Usmar VM, Russell LJ, Stone, D: Pro-oxidant effects of lipoxygenase derived peroxides on the copper-initiated oxidation of low density lipoprotein. Biochem J 1992, 282:631-634.
48. Benz DJ, Mol M, Ezaki M, Mori-Ito N, Zelan I, Miyanohara A, Friedmann T, Parthasarathy S, Steinberg D, Witztum JL: Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J Biol Chem 1995, 270:5191-5197. This paper provides, for the first time, direct evidence that overexpression of intracellular 15-LOX may lead to an increase in LDL oxidation. These data were obtained with genetically manipulated cells (15-LOX transfectants) in vitro. It remains to be established whether similar effects are also observable with natural cells expressing the 15-LOX such as interteukin-4-treated monocytes.
49. Wiesner R, Rathmann J, Holzhütter HG, Stößer R, Mäder K, Nolting H, Kühn H: Nitric oxide oxidises ferrous mammalian lipoxygenases to a preactlvated ferric species. FEBS Lett 1996, 389:229-232.
50. Chait A, Heinecke JW: Lipoprotein modification: cellular mechanisms. Curr Opin Lipidol 1994, 5:365-370.
51. Sun D, Funk C: Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. J Biol Chem 1996, 271:24055-24062. The disruption of the 12/15-LOX gene in mice is reported in this paper. Using unspecific markers for lipid peroxidation (thiobarbituric acid-reactive substances, isoprostanes), the authors showed that zymosan stimulated macrophages of these animals have a reduced LDL oxidizing capacity compared with macrophages from normal mice. The major methodological breakthrough associated with this paper is that these knockout mice may be used in the future for cross-breeding studies with other mouse atherosclerosis models such as apolipopotein E knockout mice or LDL receptor deficient mice, to examine the role of 12/15-LOX in atherogenesis in vivo.
52. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Nikkari T: Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 1995, 95:2692-2698.
53. Harats D, Kurihara H, Belloni P, Oakley H, Zoiber A, Ackley D, Cain G, Kurihara Y, Lawn R, Sigal E: Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promotor. J Clin Invest 1995, 95:1335-1344. Here the creation of transgenic mice is reported that overexpress 15-LOX in vessel wall endothelial cells, in the airway epithelium and several other tissues. These animals are available for future cross-breeding studies.
54. Harats D, Kurihara H, Levkovitz H, Sigal E: 15-lipoxygenase overexpression induces atherosclerosis in LDL deficient mice. 66th congress of the European Atherosclerosis Society, 1996, Florence, July 13 17, abstr:26.
55. Hugou I, Blin P, Henri J, Daret D, Larrue J: 15-lipoxygenaseexpression in smooth muscle cells from atherosclerotic rabbit aorta. Atherosclerosis 1995, 113:189-195.
56. Cornicelli JA, Sendobry S, Bocan T, Welch K, Tait B, Trivedi BK, Colbry N, Feinmark S: A novel 15-lipoxygenase inhibitor lacking antioxidative properties prevents atherosclerosis in cholesterol fed rabbits. XII International Symposium on Drugs Affecting Lipid Metabolism, 1995, Houston, Nov 710, abstr:54.
57. Simon TC, Makheja AN, Bailey JM: Relationship of vascular 15-lipoxygenase induction to atherosclerotic plaque formaton in rabbits. Prostaglandins, Leukot Essent Fatty Acids 1994, 41: 273-278.
58. Shen J, Kühn H, Petho-Schramm A, Chan L: Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. FASEB J 1995, 9:1623-1631. Here the creation and characterization of transgenic rabbits that overexpress the 15-LOX selectively in monocyte/macrophages is reported. In order to achieve macrophage-specific expression, a chicken lysozyme promotor was used. A drawback of this promotor is that the regulation of the expression of the transgenic 15-LOX will be different from that of the normal enzyme. On the other hand, the advantage of using this promotor is that the transgene is selectively expressed in the macrophages, in a cell in which the enzyme is induced during atherosclerosis. Thus, the role of macrophage-specific 15-LOX expression can be examined.
59. Shen J, Herderick E, Cornhill F, Zsigmond E, Kim HS, Kühn H, Guevara NV, Chan L: Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1997 (In press).
60. Simon TC, Makheja AN, Bailey MJ: The induced lipoxygenase in atherosclerotic aorta converts linoleic acid to the platelet chemorepellent factor 13-HODE. Thromb Res 1989, 55:171-178.
61. Buchanan MR, Haas TH, Lagarde M, Guichardant M: 13-Hydroxy-octadecadienoic acid is the vessel wall chemorepellent factor. J Biol Chem 1985, 260:16056-16059.
62. Lafrenie RM, Gallo S, Podor TJ, Buchanan MR: The relative roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to interleukin-1-treated endothelial cells. Eur J Cancer 1994, 30:2151-2158.
63. Buchanan MR, Brister SJ: Effects of 13-HODE and other monohydroxides on integrin/ligand binding: implication for cell cell interaction. Prostaglandins, Leukot Essent Fatty Acids 1996, 25(Suppl 1):48.
64. Setty BNY, Berger M, Stuart MJ: 13-Hydroxyoctadecadienoic acid (13-HODE) stimulates prostacyclin production by endothelial cells. Biochem Biophys Res Commun 1987, 145:502-509.
65. Setty BNY, Berger M, Stuart MJ: 13-Hydroxyoctadeca-9,11-dienoicacid (13-HODE) inhibits thromboxane A2 synthesis, and stimulates 12-HETE production in human platelets. Biochem Biophys Res Commun 1987, 148:528-533.
66. van Heuven-Nolsen D, Muis T, Engels F, Henricks PAJ, Buckley TL, Nijkamp FP: Hypotensive effect of 13-hydroxylinoleic acid in the rat: mediation via release of CGPR-like mediator from capsaicin-sensitive nerves. Br J Pharmacol 1995, 115:835-839.
67. Bates EJ, Ferrante A, Poulos A, Smithers L, Rathjen DA, Robinson BS: Inhibitory effects of arachidonic acid (20:4,n-6) and its monohydroperoxy-metabolites on procoagulant activity in endothelial cells. Atherosclerosis 1995, 116:125-133.
68. Rao GN, Alexander RW, Runge MS: Linoleic acid and its metabolites, hydroperoxyoctadecadlenolc acids, stimulate c-fos, c-jun, c-myc mRNA expression, mitogen-associated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 1995, 96:842-847. It is indicated in this study that the cellular peroxide tone may regulate gene expression. As 15-LOX is a lipid peroxidizing enzyme and probably contributes to increasing the intracellular peroxide tone, it may be of importance for the regulation of redox-sensitive genes.